The Company's Board of Directors resolved to
issue new shares through capitalization of
retained earnings
Date of events
2022/03/30
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/03/30
2.Source of capital increase funds:capitalization of 2021 earnings
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
38,061,500 NTD and 3,806,150 shares.
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:10 NTD
8.Issue price:N/A
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:50 shares gratuitously allotted
for every thousand shares.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:If the new shares distributed to
shareholders from this capitalization are less than one full share,
shareholders may register with the Company's stock transfer agent
for consolidation within five days after the book closure starting date.
For those shares not being consolidated or remaining insufficient, cash
will be distributed instead (rounded to the dollar) in accordance with
Article 240 of the Company Act, and the Chairman shall be authorized to
designate specific persons for purchase of these by cash at par value.
13.Rights and obligations of these newly issued shares:Rights and
obligations of these newly issued shares are the same as those of the
original shares.
14.Utilization of the funds from the capital increase:To enhance capital
structure for long term business development.
15.Any other matters that need to be specified:The new share issuance shall
be approved by the Company's general shareholders meeting and the
competent authority for the Broad of Directors to be authorized to set the
record date, distribution date and other matters.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Universal Vision Biotechnology Co. Ltd. published this content on 30 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2022 14:12:08 UTC.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
